טוען...
A qualitative assessment of the challenges of WHO prequalification for anti-malarial drugs in China
BACKGROUND: While China is a major manufacturer of artemisinin and its derivatives, it lags as a global leader in terms of the total export value of anti-malarial drugs as finished pharmaceutical products ready for marketing and use by patients. This may be due to the limited number of World Health...
שמור ב:
| הוצא לאור ב: | Malar J |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5883522/ https://ncbi.nlm.nih.gov/pubmed/29615066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-018-2303-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|